A Boston team has identified activating mutations in mammalian
target of rapamycin that explain a surprising 14-month
complete response seen in 1 patient with bladder cancer receiving Afinitor
in a Phase I trial.1 The findings are the latest in a string of
studies characterizing 'exceptional responders'. This year the National Cancer Institute
plans to launch an initiative to sequence 100 such patients to help identify
additional mutations that could prospectively predict drug response.
NCI and other institutions are now dedicating resources to sequence additional
patients who have had extraordinary responses.
Cain, C. SciBX 7(12);
Published online March 27, 2014
1. Wagle, N. et al. Cancer Discov.; published online
March 13, 2013; doi:10.1158/2159-8290.CD-13-0353 Contact:
Jonathan E. Rosenberg, Memorial Sloan Kettering Cancer Center, New York, N.Y. e-mail:
Contact: Levi A. Garraway, Dana-Farber Cancer
Institute, Boston, Mass. e-mail: firstname.lastname@example.org
2. Sen, B. et al. Sci. Transl. Med.
4, 136ra70 (2012)
3. Iyer, G. et al. Science 338, 221 (2012)
4. Grabiner, B.C. et al. Cancer Discov.; published online March
14, 2013; doi:10.1158/2159-8290.CD-13-0929 Contact:
David M. Sabatini, Whitehead Institute for Biomedical Research, Cambridge,
Mass. e-mail: email@example.com
AND INSTITUTIONS MENTIONED
Brigham and Women's Hospital, Boston, Mass.
Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.
Broad Institute of MIT and Harvard, Cambridge, Mass.
Dana-Farber Cancer Institute, Boston, Mass.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Harvard Medical School, Boston, Mass.
Memorial Sloan Kettering Cancer Center, New York, N.Y.
National Cancer Institute, Bethesda, Md.
Nationwide Children's Hospital, Columbus, Ohio
(NYSE:NVS; SIX:NOVN), Basel, Switzerland
Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan
Starr Cancer Consortium, New York, N.Y.